Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Decisions, Decisions: Neoadjuvant Chemotherapy, Neoadjuvant Endocrine Therapy, or Primary Surgery?

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188–94.

    Article  PubMed  Google Scholar 

  2. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cao L, Sugumar K, Keller E, Li P, Rock L, Simpson A, Freyvogel M, Montero AJ, Shenk R, Miller ME. Neoadjuvant endocrine therapy as an alternative to neoadjuvant chemotherapy among hormone receptor positive breast cancer patients: pathologic and surgical outcomes. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10459-3.

  4. Montagna G, Sevilimedu V, Fornier M, Jhaveri K, Morrow M, Pilewskie ML. How effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery? Ann Surg Oncol. 2020;27(12):4702–10.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Stafford A, Williams A, Edmiston K, et al. Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer: systematic literature review and NCDB analysis. Ann Surg Oncol. 2020;27(12):4669–77.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA

    Lifen Cao MD, PhD, Alberto J. Montero MD, MBA, Robert Shenk MD, FACS & Megan E. Miller MD, FACS

Authors
  1. Lifen Cao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto J. Montero MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Shenk MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Megan E. Miller MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Megan E. Miller MD, FACS.

Ethics declarations

Disclosures

This is an invited commentary submitted as an ASO Author Reflection. The accompanying study was presented in e-Poster format at the American Society of Breast Surgeons International Conference on Breast Cancer Care, April 29-May 2, 2021. The authors have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cao, L., Montero, A.J., Shenk, R. et al. ASO Author Reflections: Decisions, Decisions: Neoadjuvant Chemotherapy, Neoadjuvant Endocrine Therapy, or Primary Surgery?. Ann Surg Oncol 29 (Suppl 3), 562–563 (2022). https://doi.org/10.1245/s10434-021-10621-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10621-x

Search

Navigation